Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17051) 17051
Publication (1763) 1763
Book Review (540) 540
Book Chapter (49) 49
Conference Proceeding (13) 13
Dissertation (6) 6
Magazine Article (5) 5
Data Set (4) 4
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
open-label (15432) 15432
index medicus (11072) 11072
humans (10734) 10734
oncology (5982) 5982
female (4951) 4951
male (4541) 4541
double-blind (3896) 3896
middle aged (3491) 3491
chemotherapy (3463) 3463
treatment outcome (3299) 3299
adult (3109) 3109
pharmacology & pharmacy (3030) 3030
aged (2841) 2841
cancer (2781) 2781
care and treatment (2685) 2685
multicenter (2210) 2210
clinical trials (1989) 1989
efficacy (1907) 1907
1st-line treatment (1890) 1890
drug therapy (1890) 1890
analysis (1774) 1774
safety (1699) 1699
therapy (1684) 1684
patients (1592) 1592
trial (1547) 1547
medicine & public health (1542) 1542
research (1541) 1541
psychiatry (1477) 1477
mutation (1464) 1464
immunotherapy (1403) 1403
metastasis (1361) 1361
antineoplastic agents - therapeutic use (1342) 1342
clinical neurology (1321) 1321
survival (1278) 1278
health aspects (1245) 1245
aged, 80 and over (1197) 1197
antineoplastic combined chemotherapy protocols - therapeutic use (1196) 1196
animals (1116) 1116
review (1107) 1107
hematology (1099) 1099
adolescent (1089) 1089
placebo-controlled trial (1061) 1061
lung cancer (1060) 1060
cancer therapies (1051) 1051
medical research (1042) 1042
medicine, general & internal (1035) 1035
open-label trial (1013) 1013
randomized controlled trials as topic (1000) 1000
lung neoplasms - drug therapy (967) 967
tumors (952) 952
randomized controlled-trial (877) 877
young adult (874) 874
disease-free survival (872) 872
phase-iii trial (862) 862
prognosis (861) 861
carcinoma, non-small-cell lung - drug therapy (837) 837
studies (837) 837
cell lung-cancer (835) 835
gefitinib (831) 831
neurosciences (824) 824
erlotinib (801) 801
surgery (800) 800
retrospective studies (791) 791
risk factors (784) 784
child (782) 782
clinical trials as topic (780) 780
usage (779) 779
dosage and administration (777) 777
melanoma (773) 773
internal medicine (772) 772
lung cancer, non-small cell (771) 771
drug therapy, combination (750) 750
phase-iii (740) 740
protein kinase inhibitors - therapeutic use (727) 727
abridged index medicus (714) 714
phase-ii (708) 708
immunology (703) 703
medicine, experimental (702) 702
phase-ii trial (700) 700
quality-of-life (696) 696
docetaxel (691) 691
article (687) 687
medicine, research & experimental (685) 685
double-blind method (678) 678
respiratory system (677) 677
hematology, oncology and palliative medicine (668) 668
quality of life (659) 659
children (658) 658
breast cancer (657) 657
endocrinology & metabolism (655) 655
epidermal growth factor (654) 654
drug administration schedule (645) 645
adenocarcinoma (632) 632
lung neoplasms - genetics (627) 627
antibodies, monoclonal - therapeutic use (623) 623
molecular targeted therapy (616) 616
targeted therapy (610) 610
randomized-trial (609) 609
combination (605) 605
pharmacokinetics (605) 605
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16619) 16619
German (212) 212
French (118) 118
Spanish (62) 62
Italian (9) 9
Portuguese (9) 9
Turkish (8) 8
Polish (7) 7
Japanese (6) 6
Russian (5) 5
Chinese (3) 3
Korean (3) 3
Czech (2) 2
Hungarian (2) 2
Icelandic (2) 2
Slovenian (2) 2
Esperanto (1) 1
Georgian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Low-volume insulin degludec 200 Units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The begin low volume trial
by Gough, Stephen C.L and Bhargava, Anuj and Jain, Rajeev and Mersebach, Henriette and Rasmussen, SØren and Bergenstal, Richard M
Diabetes Care, ISSN 0149-5992, 09/2013, Volume 36, Issue 9, pp. 2536 - 2542
OBJECTIVE The 200 units/mL formulation of insulin degludec (IDeg 200 units/mL) contains equal units of insulin in half the volume compared with the 100... 
THERAPY | LONGACTING BASAL INSULIN | ASPART | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | U-500 INSULIN | BARRIERS | OPEN-LABEL | PHASE-3 | BOLUS TREATMENT | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Insulin - administration & dosage | Male | Treatment Outcome | Hypoglycemia - drug therapy | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Diabetes Mellitus, Type 2 - blood | Insulin, Long-Acting - administration & dosage | Hypoglycemic Agents - administration & dosage | Insulin, Long-Acting - therapeutic use | Female | Aged | Hypoglycemia - blood | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Type 2 diabetes | Glucose metabolism | Research | Glucose | Pharmaceutical industry | Insulin | Dextrose | Diabetes therapy | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Probing oral anticoagulation in patients with atrial high rate episodes. Rationale and design of the Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH – AFNET 6) trial
by Kirchhof, Paulus and Blank, Benjamin F and Calvert, Melanie and Camm, A John and Chlouverakis, Gregory and Diener, Hans-Christoph and Goette, Andreas and Huening, Andrea and Lip, Gregory Y.H and Simantirakis, Emmanuel and Vardas, Panos
American Heart Journal, ISSN 0002-8703, 2017, Volume 190, pp. 12 - 18
Background Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation. Early detection of atrial fibrillation and subsequent... 
Cardiovascular | FIBRILLATION | CARDIAC & CARDIOVASCULAR SYSTEMS | STROKE PREVENTION | WARFARIN | CLINICAL-IMPLICATIONS | AMERICAN-COLLEGE | CARDIAC MONITOR | RISK | OPEN-LABEL | TEMPORAL RELATIONSHIP | ISCHEMIC-STROKE | Prospective Studies | Follow-Up Studies | Humans | Male | Thiazoles - administration & dosage | Atrial Fibrillation - physiopathology | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Time Factors | Female | Stroke - epidemiology | Vitamin K | Heart Rate | Stroke - prevention & control | Pyridines - administration & dosage | Survival Rate - trends | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Europe - epidemiology | Treatment Outcome | Disease-Free Survival | Stroke - etiology | Atrial Fibrillation - epidemiology | Aged | Fibrinolytic Agents - administration & dosage | Stroke (Disease) | Care and treatment | Anticoagulants (Medicine) | Stroke patients | Atrial fibrillation | Cardiac patients | Implants, Artificial | Prosthesis | Anticoagulants | Therapy | Cardiac arrhythmia | Surgical implants | Aspirin | Stroke | Coagulation | Strokes | Patients | Bleeding | Risk factors | Vitamins | Artifacts | Fibrillation | Ischemia | Defibrillators | Pacemakers | Safety engineering | Electrocardiography | Heart diseases | Trial Design
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
by Papp, Kim, MD, PhD and Reich, Kristian, MD, PhD and Leonardi, Craig L., MD and Kircik, Leon, MD and Chimenti, Sergio, MD and Langley, Richard G.B., MD and Hu, ChiaChi, EdM, MS and Stevens, Randall M., MD and Day, Robert M., PhD and Gordon, Kenneth B., MD and Korman, Neil J., MD, PhD and Griffiths, Christopher E.M., MD, FMedSci
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 73, Issue 1, pp. 37 - 49
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day... 
Dermatology | clinical trial | ESTEEM | treatment | phosphodiesterase 4 inhibitor | psoriasis | apremilast | MANAGEMENT | OPEN-LABEL | ARTHRITIS | DERMATOLOGY | Severity of Illness Index | Thalidomide - analogs & derivatives | Psoriasis - drug therapy | Double-Blind Method | Administration, Oral | Phosphodiesterase 4 Inhibitors - administration & dosage | Humans | Middle Aged | Female | Male | Thalidomide - administration & dosage | Product development | Hospitals | Toiletries industry | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
by Ichihara, Eiki and Hotta, Katsuyuki and Nogami, Naoyuki and Kuyama, Shoichi and Kishino, Daizo and Fujii, Masanori and Kozuki, Toshiyuki and Tabata, Masahiro and Harada, Daijiro and Chikamori, Kenichi and Aoe, Keisuke and Ueoka, Hiroshi and Hosokawa, Shinobu and Bessho, Akihiro and Hisamoto-Sato, Akiko and Kubo, Toshio and Oze, Isao and Takigawa, Nagio and Tanimoto, Mitsune and Kiura, Katsuyuki
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2015, Volume 10, Issue 3, pp. 486 - 491
Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non–small cell lung cancers (NSCLCs)... 
MULTICENTER | CARBOPLATIN | GROWTH-FACTOR-RECEPTOR | TYROSINE KINASE | SENSITIVITY | OPEN-LABEL | KINASE INHIBITOR | CHEMOTHERAPY | Bevacizumab | PACLITAXEL | ONCOLOGY | RESPIRATORY SYSTEM | Epidermal growth factor mutation | Non-small cell lung cancer | Gefitinib | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prospective Studies | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Case-Control Studies | Neoplasm Grading | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Survival Rate | Mutation - genetics | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Adenocarcinoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
by Soria, Jean-Charles, Prof and Wu, Yi-Long, Prof and Nakagawa, Kazuhiko, Prof and Kim, Sang-We, Prof and Yang, Jin-Ji, MD and Ahn, Myung-Ju, Prof and Wang, Jie, MD and Yang, James Chih-Hsin, Prof and Lu, You, Prof and Atagi, Shinji, MD and Ponce, Santiago, MD and Lee, Dae Ho, Prof and Liu, Yunpeng, Prof and Yoh, Kiyotaka, MD and Zhou, Jian-Ying, Prof and Shi, Xiaojin, MD and Webster, Alan, MSc and Jiang, Haiyi, MD and Mok, Tony S K, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
by Untch, Michael, Prof and Jackisch, Christian, Prof and Schneeweiss, Andreas, Prof and Conrad, Bettina, MD and Aktas, Bahriye, MD and Denkert, Carsten, Prof and Eidtmann, Holger, MD and Wiebringhaus, Hermann, MD and Kümmel, Sherko, MD and Hilfrich, Jörn, Prof and Warm, Mathias, Prof and Paepke, Stefan, MD and Just, Marianne, MD and Hanusch, Claus, MD and Hackmann, John, MD and Blohmer, Jens-Uwe, Prof and Clemens, Michael, Prof and Darb-Esfahani, Silvia, MD and Schmitt, Wolfgang Daniel, MD and Dan Costa, Serban, Prof and Gerber, Bernd, Prof and Engels, Knut, MD and Nekljudova, Valentina, PhD and Loibl, Sibylle, Prof and von Minckwitz, Gunter, Prof and Arbeitsgemeinschaft Gynakologische and German Breast Grp GBG Investigator and German Breast Group (GBG) and Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 345 - 356
Summary Background In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based... 
Hematology, Oncology and Palliative Medicine | EVERY 3 WEEKS | WOMEN | ONCOLOGY | CYCLOPHOSPHAMIDE | ALBUMIN-BOUND PACLITAXEL | HIGH-RISK | OPEN-LABEL | SPARC EXPRESSION | DOCETAXEL | PLUS TRASTUZUMAB | PATHOLOGICAL COMPLETE RESPONSE | Breast Neoplasms - surgery | Confidence Intervals | Prognosis | Drug Administration Schedule | Risk Assessment | Humans | Middle Aged | Mastectomy - methods | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Dose-Response Relationship, Drug | Albumins - therapeutic use | Disease-Free Survival | Albumins - adverse effects | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Aged | Infusions, Intravenous | Anthracyclines | Cyclophosphamide | Adjuvant treatment | Product development | Breast cancer | Metastasis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
by Zinman, Bernard and Philis-Tsimikas, Athena and Cariou, Bertrand and Handelsman, Yehuda and Rodbard, Helena W and Johansen, Thue and Endahl, Lars and Mathieu, Chantal and NN1250-3579 Begin Once Long Trial and NN1250-3579 (BEGIN Once Long) Trial Investigators and on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators
Diabetes Care, ISSN 0149-5992, 12/2012, Volume 35, Issue 12, pp. 2464 - 2471
OBJECTIVE-To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately... 
NPH INSULIN | THERAPY | MANAGEMENT | LONGACTING BASAL INSULIN | ASPART | EFFICACY | ENDOCRINOLOGY & METABOLISM | HYPOGLYCEMIA | OPEN-LABEL | REGIMENS | BOLUS TREATMENT | Hypoglycemic Agents - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Treatment Outcome | Diabetes Mellitus, Type 2 - metabolism | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Insulin Glargine | Insulin, Long-Acting - therapeutic use | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Insulin - therapeutic use | Type 2 diabetes | Physiological aspects | Hypoglycemic agents | Dosage and administration | Drug therapy | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase II trial of cabozantinib plus erlotinib in patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer with progressive disease on epidermal growth factor receptor tyrosine kinase inhibitor therapy: A California cancer consortium phase II trial (NCI 9303)
by Reckamp, Karen L and Frankel, Paul H and Ruel, Nora and Mack, Philip C and Gitlitz, Barbara J and Li, Tianhong and Koczywas, Marianna and Gadgeel, Shirish M and Cristea, Mihaela C and Belani, Chandra P and Newman, Edward M and Gandara, David R and Lara, Primo N
Frontiers in Oncology, ISSN 2234-943X, 2019, Volume 9, p. 132
Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor pathways are important in mediating non-small cell lung cancer (NSCLC)... 
RET | TKI resistance | MET | VEGF | EGFR | Non-small cell lung cancer | non-small cell lung cancer | GEFITINIB | MULTICENTER | XL184 | ACQUIRED-RESISTANCE | OPEN-LABEL | EGFR MUTATIONS | MET AMPLIFICATION | ONCOLOGY | Erlotinib | Gene mutations | Development and progression | Dosage and administration | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia : A Randomized Clinical Trial
by Subotnik, Kenneth L and Casaus, Laurie R and Ventura, Joseph and Luo, John S and Hellemann, Gerhard S and Gretchen-Doorly, Denise and Marder, Stephen and Nuechterlein, Keith H
JAMA Psychiatry, ISSN 2168-622X, 08/2015, Volume 72, Issue 8, pp. 822 - 829
IMPORTANCE: Long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with... 
MAINTENANCE TREATMENT | INJECTION | PSYCHIATRY | SCHIZOAFFECTIVE DISORDER | OPEN-LABEL | 1ST-EPISODE SCHIZOPHRENIA | ORAL RISPERIDONE | REMISSION | Early Medical Intervention - methods | Administration, Oral | Humans | Risperidone - administration & dosage | Male | Treatment Outcome | Combined Modality Therapy | Secondary Prevention - methods | Health Behavior | Antipsychotic Agents - administration & dosage | Young Adult | Medication Adherence | Risperidone - therapeutic use | Antipsychotic Agents - therapeutic use | Schizophrenia - prevention & control | Delayed-Action Preparations - therapeutic use | Cognitive Therapy | Female | Schizophrenia - drug therapy | Symptomatology | Care and treatment | Usage | Analysis | Schizophrenia | Clinical trials | Dosage and administration | Risperidone
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial
by Stupp, Roger and Taillibert, Sophie and Kanner, Andrew A and Kesari, Santosh and Steinberg, David M and Toms, Steven A and Taylor, Lynne P and Lieberman, Frank and Silvani, Antonio and Fink, Karen L and Barnett, Gene H and Zhu, Jay-Jiguang and Henson, John W and Engelhard, Herbert H and Chen, Thomas C and Tran, David D and Sroubek, Jan and Tran, Nam D and Hottinger, Andreas F and Landolfi, Joseph and Desai, Rajiv and Caroli, Manuela and Kew, Yvonne and Honnorat, Jerome and Idbaih, Ahmed and Kirson, Eilon D and Weinberg, Uri and Palti, Yoram and Hegi, Monika E and Ram, Zvi
JAMA, ISSN 0098-7484, 12/2015, Volume 314, Issue 23, pp. 2535 - 2543
IMPORTANCE: Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of... 
PHASE-III TRIAL | ALTERNATING ELECTRIC-FIELDS | NOVOTTF-100A | MEDICINE, GENERAL & INTERNAL | TREATMENT MODALITY | NEWLY-DIAGNOSED GLIOBLASTOMA | RECURRENT GLIOBLASTOMA | OPEN-LABEL | QUALITY-OF-LIFE | RADIOTHERAPY | ADJUVANT TEMOZOLOMIDE | Dacarbazine - therapeutic use | United States | Humans | Middle Aged | Male | Chemoradiotherapy | Young Adult | Early Termination of Clinical Trials | Carmustine - therapeutic use | Maintenance Chemotherapy - methods | Dacarbazine - analogs & derivatives | Aged, 80 and over | Adult | Female | Brain Neoplasms - mortality | Republic of Korea | Europe | Combined Modality Therapy - adverse effects | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Glioblastoma - therapy | Canada | Disease-Free Survival | Electric Stimulation Therapy - methods | Electric Stimulation Therapy - adverse effects | Brain Neoplasms - therapy | Aged | Combined Modality Therapy - methods | Israel | Glioblastoma - mortality | Patient safety | Brain cancer | Medical treatment | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
by Stupp, Roger and Taillibert, Sophie and Kanner, Andrew and Read, William and Steinberg, David M and Lhermitte, Benoit and Toms, Steven and Idbaih, Ahmed and Ahluwalia, Manmeet S and Fink, Karen and Di Meco, Francesco and Lieberman, Frank and Zhu, Jay-Jiguang and Stragliotto, Giuseppe and Tran, David D and Brem, Steven and Hottinger, Andreas F and Kirson, Eilon D and Lavy-Shahaf, Gitit and Weinberg, Uri and Kim, Chae-Yong and Paek, Sun-Ha and Nicholas, Garth and Bruna, Jordi and Hirte, Hal and Weller, Michael and Palti, Yoram and Hegi, Monika E and Ram, Zvi
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
IMPORTANCE: Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by... 
PHASE-III TRIAL | MALIGNANT GLIOMA | MEDICINE, GENERAL & INTERNAL | BEVACIZUMAB | NEWLY-DIAGNOSED GLIOBLASTOMA | CENTRAL-NERVOUS-SYSTEM | OPEN-LABEL | QUALITY-OF-LIFE | RADIOTHERAPY | BRAIN | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Mitosis | Humans | Middle Aged | Male | Electric Stimulation Therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Glioblastoma - surgery | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Dacarbazine - analogs & derivatives | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Temozolomide | Antineoplastic Agents, Alkylating - adverse effects | Glioblastoma - drug therapy | Chemotherapy | Usage | Patient outcomes | Dosage and administration | Drug therapy | Glioblastoma multiforme | Cancer | Statistical analysis | Toxicity | Glioblastoma | Central nervous system | Clinical trials | Cell division | Nervous system | Maintenance | Patients | Survival | Randomization | Scalp | Skin | Portable equipment | Electric fields | Tumors | Original Investigation | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
by Cameron, David, Prof and Piccart-Gebhart, Martine J, PhD and Gelber, Richard D, PhD and Procter, Marion, PhD and Goldhirsch, Aron, MD and de Azambuja, Evandro, MD and Castro, Gilberto, MD and Untch, Michael, MD and Smith, Ian, MD and Gianni, Luca, MD and Baselga, Jose, MD and Al-Sakaff, Nedal, PhD and Lauer, Sabine, PhD and McFadden, Eleanor, MA and Leyland-Jones, Brian, MBBS and Bell, Richard, MBBS and Dowsett, Mitch, PhD and Jackisch, Christian, MD and Herceptin Adjuvant HERA Trial and Herceptin Adjuvant (HERA) Trial Study Team
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall... 
Internal Medicine | SYSTEM | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PHASE-3 TRIAL | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | PERTUZUMAB | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Laboratories | Toxicity | Medical services | Clinical trials | Cancer therapies | Incidence | Motivation | Failure analysis | Surgery | Heart diseases | Recombinant | Medical research | Health risks | Mammography | Radiation therapy | Patients | Survival | ErbB-2 protein | Chemotherapy | Breast | Informed consent | Trastuzumab | Schedules | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights